JP2008535902A5 - - Google Patents

Download PDF

Info

Publication number
JP2008535902A5
JP2008535902A5 JP2008505964A JP2008505964A JP2008535902A5 JP 2008535902 A5 JP2008535902 A5 JP 2008535902A5 JP 2008505964 A JP2008505964 A JP 2008505964A JP 2008505964 A JP2008505964 A JP 2008505964A JP 2008535902 A5 JP2008535902 A5 JP 2008535902A5
Authority
JP
Japan
Prior art keywords
group
compound according
optionally substituted
treatment
attached
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008505964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535902A (ja
Filing date
Publication date
Priority claimed from GB0507831A external-priority patent/GB0507831D0/en
Application filed filed Critical
Priority claimed from PCT/GB2006/001369 external-priority patent/WO2006109081A1/en
Publication of JP2008535902A publication Critical patent/JP2008535902A/ja
Publication of JP2008535902A5 publication Critical patent/JP2008535902A5/ja
Pending legal-status Critical Current

Links

JP2008505964A 2005-04-15 2006-04-13 Dna−pk阻害剤 Pending JP2008535902A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US67188605P 2005-04-15 2005-04-15
US67183005P 2005-04-15 2005-04-15
GB0507831A GB0507831D0 (en) 2005-04-18 2005-04-18 DNA-PK inhibitors
US69606405P 2005-07-01 2005-07-01
US71890405P 2005-09-20 2005-09-20
PCT/GB2006/001369 WO2006109081A1 (en) 2005-04-15 2006-04-13 Dna-pk inhibitors

Publications (2)

Publication Number Publication Date
JP2008535902A JP2008535902A (ja) 2008-09-04
JP2008535902A5 true JP2008535902A5 (cg-RX-API-DMAC7.html) 2009-04-30

Family

ID=36579227

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008505966A Pending JP2008535903A (ja) 2005-04-15 2006-04-13 Dna−pk阻害剤
JP2008505964A Pending JP2008535902A (ja) 2005-04-15 2006-04-13 Dna−pk阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008505966A Pending JP2008535903A (ja) 2005-04-15 2006-04-13 Dna−pk阻害剤

Country Status (13)

Country Link
US (2) US7696203B2 (cg-RX-API-DMAC7.html)
EP (2) EP1869040A1 (cg-RX-API-DMAC7.html)
JP (2) JP2008535903A (cg-RX-API-DMAC7.html)
KR (1) KR20080002963A (cg-RX-API-DMAC7.html)
AR (2) AR053358A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006235731A1 (cg-RX-API-DMAC7.html)
CA (1) CA2603637A1 (cg-RX-API-DMAC7.html)
IL (1) IL186445A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007012696A (cg-RX-API-DMAC7.html)
NO (1) NO20075809L (cg-RX-API-DMAC7.html)
TW (2) TW200720271A (cg-RX-API-DMAC7.html)
UY (1) UY29479A1 (cg-RX-API-DMAC7.html)
WO (2) WO2006109081A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
ATE461193T1 (de) * 2003-08-13 2010-04-15 Kudos Pharm Ltd Aminopyrone und ihre verwendung als atm inhibitoren
US7402607B2 (en) 2004-09-20 2008-07-22 Kudos Pharmaceuticals Limited DNA-PK inhibitors
TW200638938A (en) * 2005-02-09 2006-11-16 Kudos Pharm Ltd ATM inhibitors
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
EP2198710A1 (de) 2008-12-19 2010-06-23 Bayer CropScience AG Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze
WO2010136778A1 (en) * 2009-05-29 2010-12-02 Kudos Pharmaceuticals Limited Dibenzothiophene derivatives as dna- pk inhibitors
FR2947551B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
FR2951170B1 (fr) * 2009-10-09 2011-12-02 Sanofi Aventis Nouveaux derives de 1h-pyrimidin-2-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2947550B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
FR2947548B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 1h-pyrimidin-2-one, leur preparation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
CA2767064C (fr) 2009-07-02 2017-11-07 Sanofi Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
WO2011001115A1 (fr) 2009-07-02 2011-01-06 Sanofi-Aventis Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4- ( 3h ) -one, leur preparation pharmaceutique comme inhibiteurs de phos phorylat i on d ' akt ( pkb )
ES2487623T3 (es) 2009-07-02 2014-08-22 Sanofi Derivados de 6,7,8,9-tetrahidro-pirimido{1,2-a}pirimidin-4-ona, su preparación y su aplicación farmacéutica
HUE034503T2 (en) 2009-07-02 2018-02-28 Sanofi Sa 2,3-Dihydro-1-imidazo [1,2-a] pyrimidin-5-one derivatives, their preparation process and their use in medicine
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
MX341957B (es) 2010-04-15 2016-09-08 3M Innovative Properties Co Articulos retrorreflectantes que incluyen areas opticamente activas y areas opticamente inactivas.
US20130109687A1 (en) * 2010-04-30 2013-05-02 Gary J. Nabel Methods of treating hiv infection: inhibition of dna dependent protein kinase
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
PL2655375T3 (pl) 2010-12-23 2015-05-29 Sanofi Sa Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie
ES2612492T3 (es) 2010-12-28 2017-05-17 Sanofi Nuevos derivados de piridiminas, su preparación y su utilización farmacéutica como inhibidores de fosforilación de AKT (PKB)
UY34013A (es) * 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
LT2841428T (lt) 2012-04-24 2018-12-10 Vertex Pharmaceuticals Incorporated Dnr-pk inhibitoriai
EP2861589B1 (en) * 2012-06-15 2017-05-17 Basf Se Multicomponent crystals comprising dasatinib and selected cocrystal formers
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
FR2992316A1 (fr) 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
CN105246883B (zh) 2013-03-12 2017-07-21 沃泰克斯药物股份有限公司 Dna‑pk抑制剂
BR112017011335A2 (pt) * 2014-12-02 2018-02-20 Prana Biotechnology Limited compostos de 4h-pirido[1,2-a]pirimidin-4-ona
TW201815418A (zh) 2016-09-27 2018-05-01 Vertex Pharma 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法
CN109232476B (zh) * 2018-11-06 2020-06-26 常州大学 一种制备n-苯基-3-吗啡啉丙酰胺的方法
WO2021184014A1 (en) * 2020-03-13 2021-09-16 Arizona Board Of Regetns On Behalf Of The University Of Arizona Stable reactive compositions for bioconjugation, probes, and protein labeling
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1303724A (cg-RX-API-DMAC7.html) 1969-05-14 1973-01-17
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
RU2118321C1 (ru) 1988-12-21 1998-08-27 Дзе Апджон Компани Замещенные бензопираноны и их фармацевтически приемлемые соли и гидраты
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
JPH03215423A (ja) 1990-01-18 1991-09-20 Kyowa Hakko Kogyo Co Ltd 血管拡張剤
CA2081577A1 (en) 1990-06-20 1991-12-21 Ronald B. Gammill Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1, 3-benzoxazine-4-ones
US5302613A (en) 1990-06-29 1994-04-12 The Upjohn Company Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US5252735A (en) 1990-06-29 1993-10-12 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
JPH05501886A (ja) 1990-06-29 1993-04-08 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化症性および抗血栓性2―アミノ―6―フェニル―4h―ピラン―4―オン類
EP0610519B1 (en) 1992-09-02 1999-12-01 Kyowa Hakko Kogyo Co., Ltd. Anti-hiv drug
AU698990B2 (en) * 1993-04-09 1998-11-19 Toyama Chemical Co. Ltd. Immunomodulator, cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5504103A (en) 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
CA2133815A1 (en) 1993-10-12 1995-04-13 Jeffrey Alan Dodge Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US6632789B1 (en) 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
IL121306A0 (en) 1995-11-16 1998-01-04 Icos Corp Cell cycle checkpoint pik-related kinase materials and methods
GB2302021A (en) 1996-10-16 1997-01-08 Lilly Co Eli Inhibiting bone loss or resorption
CA2292540A1 (en) 1997-06-06 1998-12-10 Jann N. Sarkaria Screening for phosphatidylinositol related-kinase inhibitors
WO1998056391A1 (en) 1997-06-13 1998-12-17 President And Fellows Of Harvard College Methods for treating human cancers
FR2776291B1 (fr) 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6348311B1 (en) * 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
US6387640B1 (en) 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
US6333180B1 (en) * 1999-12-21 2001-12-25 International Flavors & Fragrances Inc. Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate
CN1891693A (zh) 2000-01-24 2007-01-10 基纳西亚股份有限公司 用于治疗的吗啉代基取代的化合物
KR20030017569A (ko) 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
US7179912B2 (en) 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
ES2236481T3 (es) 2001-01-16 2005-07-16 Glaxo Group Limited Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer.
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US6908932B2 (en) 2001-10-24 2005-06-21 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
AU2002357667A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
PT1485377E (pt) 2002-02-25 2010-03-12 Kudos Pharm Ltd Piranonas úteis como inibidores da atm
US7049313B2 (en) * 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
ATE461193T1 (de) 2003-08-13 2010-04-15 Kudos Pharm Ltd Aminopyrone und ihre verwendung als atm inhibitoren
US7402607B2 (en) 2004-09-20 2008-07-22 Kudos Pharmaceuticals Limited DNA-PK inhibitors
TW200638938A (en) 2005-02-09 2006-11-16 Kudos Pharm Ltd ATM inhibitors
AR053358A1 (es) 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones

Similar Documents

Publication Publication Date Title
JP2008535902A5 (cg-RX-API-DMAC7.html)
JP2008535903A5 (cg-RX-API-DMAC7.html)
ES2639064T3 (es) Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1(2h)-ona sustituidos como inhibidores de cinasa
ES2923875T3 (es) Moduladores de la vía integrada del estrés
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
JP2011509949A5 (cg-RX-API-DMAC7.html)
JP2008001718A5 (cg-RX-API-DMAC7.html)
NZ700583A (en) Novel 7-deazapurine nucleosides for therapeutic uses
JP2008526999A5 (cg-RX-API-DMAC7.html)
JP2009541223A5 (cg-RX-API-DMAC7.html)
NO2016021I1 (no) 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2Hpyrido[2,3-D]pyrimidinderivater og relaterte forbindelser for behandling av kreft
JP2010504346A5 (cg-RX-API-DMAC7.html)
JP2014513704A5 (cg-RX-API-DMAC7.html)
JP2010241830A5 (cg-RX-API-DMAC7.html)
JP2009534408A5 (cg-RX-API-DMAC7.html)
JP2006519827A5 (cg-RX-API-DMAC7.html)
ATE437872T1 (de) Proteinkinaseinhibitoren
JP2006506443A5 (cg-RX-API-DMAC7.html)
HRP20150489T1 (hr) Imidazo[4,5-c]kinolini kao inhibitori dna-pk
JP2015512943A5 (cg-RX-API-DMAC7.html)
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
RU2007110629A (ru) Ингибиторы днк-пк
EA200800516A1 (ru) Производные n-фенил-2-пиримидинамина и процесс их получения
JP2015502371A5 (cg-RX-API-DMAC7.html)
MX2007013624A (es) Inhibidores de proteina cinasa.